<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03809481</url>
  </required_header>
  <id_info>
    <org_study_id>ERGCR-18-ORGHIT-001</org_study_id>
    <nct_id>NCT03809481</nct_id>
  </id_info>
  <brief_title>Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate Safety and Efficacy of Danaparoid vs Argatroban</brief_title>
  <acronym>HITSOVA</acronym>
  <official_title>An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects With Acute HIT (HITSOVA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aspen Global Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aspen Global Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the&#xD;
      Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT&#xD;
      (HITSOVA study)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      To show that for the treatment of subjects with acute heparin-induced thrombocytopenia (HIT)&#xD;
      danaparoid use is not inferior to argatroban in terms of efficacy. The primary efficacy&#xD;
      endpoint (composite endpoint) is defined as treatment response at Day 44.&#xD;
&#xD;
      A subject will be considered a treatment responder, if none of the following events occur by&#xD;
      Day 44:&#xD;
&#xD;
        -  New or extended venous and/or arterial thrombosis, including gangrene/skin necrosis&#xD;
           Note: 'thrombosis' denotes venous and/or arterial here and throughout the protocol&#xD;
&#xD;
        -  All-cause mortality&#xD;
&#xD;
        -  Unplanned amputation, including ischemic gut resection&#xD;
&#xD;
      Secondary/Exploratory:&#xD;
&#xD;
      To collect additional efficacy data&#xD;
&#xD;
        -  Percentage of subjects with increase in platelet count to values ≥ 100,000/ μL at day 14&#xD;
&#xD;
        -  Deaths due to TE or bleeding up until Day 44&#xD;
&#xD;
        -  Incidence of fatal or non-fatal major bleeding up until Day 44&#xD;
&#xD;
      Note: As outlined by the Control of Anticoagulation Subcommittee major bleeding in&#xD;
      non-surgical subjects is defined as:&#xD;
&#xD;
        1. Fatal bleeding, and/or&#xD;
&#xD;
        2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal,&#xD;
           intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with&#xD;
           compartment syndrome, and/or&#xD;
&#xD;
        3. Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/ L) or more, or leading&#xD;
           to transfusion of two or more units of whole blood or red cells&#xD;
&#xD;
             -  New or extended thrombosis, including gangrene/skin necrosis&#xD;
&#xD;
             -  Unplanned amputation, including ischemic gut resection&#xD;
&#xD;
             -  All-cause mortality&#xD;
&#xD;
      Exploratory&#xD;
&#xD;
        -  Time to first event (new/extended thrombosis, all cause mortality, unplanned amputation)&#xD;
&#xD;
        -  Time to reach consistent increase in 3 consecutive alternate day platelet count&#xD;
           measurements during acute treatment&#xD;
&#xD;
        -  Incidence of new or extended TE events, including gangrene/skin necrosis up until Day 14&#xD;
&#xD;
        -  Incidence of all-cause mortality up until Day 14&#xD;
&#xD;
        -  Incidence of unplanned amputation up until Day 14&#xD;
&#xD;
        -  Incidence of fatal or non-fatal major bleeding up until Day 14&#xD;
&#xD;
      To describe the safety of danaparoid in comparison to argatroban&#xD;
&#xD;
        -  All-cause mortality&#xD;
&#xD;
        -  Incidence of fatal and non-fatal major bleeding events (as defined above) during the&#xD;
           acute treatment and then the entire follow-up period (until Day 44)&#xD;
&#xD;
        -  Incidence of serious adverse events (SAEs)&#xD;
&#xD;
        -  Incidence of adverse events (AEs)&#xD;
&#xD;
        -  Changes in vital parameters (heart rate, blood pressure, and respiratory rate) and&#xD;
           12-lead electrocardiogram (ECG)&#xD;
&#xD;
        -  Incidence of positive pre-danaparoid cross reactivity in the Heparin-induced Platelet&#xD;
           Activation (HIPA) assay (Greinacher. 1991)&#xD;
&#xD;
        -  Safety laboratory parameters&#xD;
&#xD;
      Design:&#xD;
&#xD;
      This is a Phase 3, open-label, randomized, active-controlled, multi-center study to evaluate&#xD;
      the safety and efficacy of danaparoid versus argatroban in treatment of subjects with&#xD;
      acuteHIT.&#xD;
&#xD;
      Subjects who develop a reduction in platelet count (PC) greater than or equal to 30% compared&#xD;
      with the higher of their pre-heparin treatment count or their highest platelet count after&#xD;
      the start of heparin either&#xD;
&#xD;
        1. Between Days 4 and 14 of the start of heparin treatment with or without thrombosis or&#xD;
&#xD;
        2. At Day 1 of heparin treatment and recent heparin exposure (within the last 30 days with&#xD;
           or without thrombosis) and who have a score on the 4Ts test of &gt;3 will be considered for&#xD;
           study enrollment as a Suspected HIT.&#xD;
&#xD;
      Subjects who have tested negative in available screening tests for HIT within the last 48&#xD;
      hours before enrollment will not be considered for study enrollment, unless new clinical&#xD;
      symptoms occurred.The following will occur for all subjects (regardless of whether they had a&#xD;
      screening HIT test performed in the enrolling hospital or not):&#xD;
&#xD;
        1. All heparin administration must be ceased after strong clinical suspicion of HIT, based&#xD;
           on clinical evaluation of the subject, including the use of heparin-bonded vascular&#xD;
           access catheters and circuits as well as heparin flushes.&#xD;
&#xD;
        2. Subject must be randomized into the study and treated with the study drug or transferred&#xD;
           to alternative non-heparin anticoagulant in situations where study drug cannot be&#xD;
           started within 2 hours after stop of heparin.&#xD;
&#xD;
        3. A blood sample may be taken at the same time for HIT testing according to local&#xD;
           practice.&#xD;
&#xD;
        4. The investigator will assess the subject for eligibility for the HITSOVA study by&#xD;
           clinical criteria (4T score &gt;3) and inclusion and exclusion criteria.&#xD;
&#xD;
        5. If eligible, written informed consent will be obtained from the subject or a legal&#xD;
           guardian and the subject will be randomized to receive study drug. .&#xD;
&#xD;
        6. A new blood sample for HIPA/ PF4/heparin IgG ELISA and anti-danaparoid antibodies and&#xD;
           cross reactivity has to be obtained to allow consistent blood sample labelling and&#xD;
           documentation before start of study drug, regardless whether another blood sample for&#xD;
           HIT testing according to local practice had been obtained at the time of suspicion of&#xD;
           HIT&#xD;
&#xD;
      Note, although use of non-heparin treatment for suspected HIT is allowed before enrollment of&#xD;
      the subject into the HITSOVA study, the study drug should be started as soon as possible, but&#xD;
      no later than 48 hours. In such situation, all time points specified in this protocol, will&#xD;
      be calculated from the time of first dose of study drug.&#xD;
&#xD;
      HIT diagnosis will be confirmed serologically by the HIPA assay and a specific PF4/heparin&#xD;
      IgG ELISA test for the HIT IgG by the nominated central laboratory based in Greifswald,&#xD;
      Germany Subjects with a positive HIPA assay and a positive HIT IgG antigen test with optical&#xD;
      density (OD) &gt; 0.5 will be classified as confirmed HIT, and treatment with randomized study&#xD;
      drug will continue.Subjects with negative HIPA assay and a positive HIT IgG antigen test with&#xD;
      an optical density (OD) &gt;0.5 and subjects with a positive HIPA assay but a negative HIT IgG&#xD;
      antigen test OD ≤0.5 will be classified as suspected HIT and treatment with randomized study&#xD;
      drug will continue. These subjects will later be adjudicated retrospectively by the&#xD;
      Adjudication Committee (AdjC) and then grouped into highly likely HIT or non-HIT.&#xD;
&#xD;
      All other subjects will be considered as non-HIT and the subjects will be removed from the&#xD;
      protocol, study drug will be discontinued, and further procedures and treatment will be given&#xD;
      at the discretion of the Investigator according to local standard practice. These subjects&#xD;
      will be followed to Day 44 after their first dose of study drug for assessment of safety.&#xD;
&#xD;
      During the treatment period if it becomes necessary for an operation, invasive vascular&#xD;
      procedure or acute kidney injury requiring the use of an extracorporeal circulation machine&#xD;
      develops, then specific dosing instructions are available.&#xD;
&#xD;
      If the acute kidney injury does not recover during the treatment period and the use of an&#xD;
      extracorporeal circulation machine is required longer, then the subject will not be eligible&#xD;
      to be included in the per protocol set (PPS), but will still be eligible to be included in&#xD;
      the full analysis set (FAS).&#xD;
&#xD;
      Study Population:&#xD;
&#xD;
      All subjects who develop a reduction in platelet count (PC) ≥ 30% compared to the higher of&#xD;
      their pre-heparin treatment count or their highest platelet count after the start of heparin&#xD;
      at either&#xD;
&#xD;
      a) between Days 4 and 14 of the start of heparin treatment with or without thrombosis or b)&#xD;
      at Day 1 of heparin treatment (and recent heparin exposure within the last 30 days) with or&#xD;
      without thrombosis and who have a score on the 4Ts test of &gt;3 and who are later suspected HIT&#xD;
      by the HIPA assay or HIT IgG..&#xD;
&#xD;
      Clinical signs of HIT are&#xD;
&#xD;
        -  New thrombosis, on either side (arterial or venous) of the circulation&#xD;
&#xD;
        -  Acute systemic reaction when heparin infusion was given:&#xD;
&#xD;
             -  Fever&#xD;
&#xD;
             -  Chills&#xD;
&#xD;
             -  High blood pressure&#xD;
&#xD;
             -  Tachycardia&#xD;
&#xD;
             -  Shortness of breath&#xD;
&#xD;
             -  Chest pain&#xD;
&#xD;
        -  Transient global amnesia&#xD;
&#xD;
        -  White clot syndrome&#xD;
&#xD;
        -  Skin necrosis&#xD;
&#xD;
        -  Occlusion of an extracorporeal circuit&#xD;
&#xD;
      Pediatric subjects will not be included in every country in this study. The countries that&#xD;
      allow inclusion of pediatric patients are France, USA,and Italy.&#xD;
&#xD;
      It is anticipated that some subjects will be dosed with alternative non-heparin&#xD;
      anti-coagulants prior to completing enrollment steps for this study. These subjects can be&#xD;
      enrolled in the study as long as the exposure to those treatments is less than 48 hours.&#xD;
&#xD;
      Baseline/screening (Day 0) and enrollment into the study (Day1) can occur on the same day. In&#xD;
      this case the assesments for Day 0 and Day 1, should only be performed once.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 16, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label, randomized, active-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Efficacy Response</measure>
    <time_frame>Day 44</time_frame>
    <description>Efficacy will be assessed by the number of subjects with suspected HIT who respond to treatment. A responder is defined as a subject who has not experienced any of the following from Day 1 to Day 44:&#xD;
New or extended venous and/or arterial thrombosis, including gangrene/skin necrosis&#xD;
All-cause mortality&#xD;
Unplanned amputation, including ischemic gut resection&#xD;
Efficacy endpoints as defined above will be assessed by clinical exam with special attention to assessments for thromboses, gangrene, and skin necrosis. Clinically suspected thrombosis will be confirmed/ruled out by objective measures, e.g. compression ultrasound.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Consistent increases in platelet count</measure>
    <time_frame>Days 14</time_frame>
    <description>Percentage of subjects with increase in platelet count to values ≥ 100,000/ μL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to TE or bleeding</measure>
    <time_frame>Day 44</time_frame>
    <description>Death due to TE or bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>Day 44</time_frame>
    <description>Incidence of fatal or non-fatal major bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New or extended thrombosis</measure>
    <time_frame>Day 44</time_frame>
    <description>New of extended thrombosis, including gangrene/skin necrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned amputation</measure>
    <time_frame>Day 44</time_frame>
    <description>Unplanned amputation, including ischemic gut resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Day 44</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">508</enrollment>
  <condition>Heparin-induced Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Danaparoid Sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive danaparoid via IV infusion for at least 7 days then transition to a VKA. IV loading bolus injection of 2250 U, followed by 400 U/h for 4 hours, then 300 U/h for 4 hours, then a maintenance infusion of 150-200 U/h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Argatroban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive argatroban 2 microgram/kg/min as a continuous infusion, titrated to an aPTT that is 1.5 to 3.0 x initial baseline value, but not exceeding 100 seconds.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danaparoid Sodium</intervention_name>
    <description>inhibits thrombin generation by indirect anti-Xa inhibition and direct inhibition of factor IX activation</description>
    <arm_group_label>Danaparoid Sodium</arm_group_label>
    <other_name>Orgaran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Argatroban</intervention_name>
    <description>Synthetic direct thrombin inhibitor</description>
    <arm_group_label>Argatroban</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        At the time of enrollment subjects are eligible to be included in the study only if all of&#xD;
        the following criteria apply:&#xD;
&#xD;
          1. Signed written informed consent by the subject who is able to assess the nature,&#xD;
             significance and scope of the clinical trial. If the subject is in emergency situation&#xD;
             and temporarily incapable of consent, the consent of a legal representative or&#xD;
             authorized representative will be waived if permitted under applicable local&#xD;
             regulations/ethics committee recommendations. Consent must be obtained for further&#xD;
             participation in the clinical trial as soon as this is possible and reasonable for the&#xD;
             subject to do so to confirm understanding/willingness to participate in the clinical&#xD;
             study and ability to comply with study procedures and the study visit schedule.&#xD;
&#xD;
          2. Males or females aged ≥2 weeks&#xD;
&#xD;
          3. Subjects with suspected HIT by 4Ts of &gt;3 and with reduction of platelet count of ≥ 30%&#xD;
             at either:&#xD;
&#xD;
               1. Between Day 4 and 14 of the start of heparin exposure or&#xD;
&#xD;
               2. At Day 1 of heparin exposure with pre-treatment with heparin within the last 30&#xD;
                  days, with or without thrombosis.&#xD;
&#xD;
          4. Have adequate renal function: estimated glomerular filtration rate (eeGFR) ≥ 15&#xD;
             mL/min/1.73 m²&#xD;
&#xD;
          5. Male participants:&#xD;
&#xD;
             A male participant must agree to use contraception during the treatment period and for&#xD;
             at least 5 days after the last dose of study intervention and refrain from donating&#xD;
             sperm during this period.&#xD;
&#xD;
          6. Female participants: female participant is eligible to participate if 1 of the&#xD;
             following conditions applies:&#xD;
&#xD;
        Not a woman of childbearing potential or A woman of childbearing potential who agrees to&#xD;
        follow the contraceptive guidance during the treatment period and during the entire VKA use&#xD;
        and for one month after cessation of its use. Subjects should continue with adequate&#xD;
        contraception after the study end if they continue with VKA use. (Subjects taking oral&#xD;
        contraceptives or hormone replacement therapy must have a stable dose and regimen for ≥ 3&#xD;
        months prior to entry into the study.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        At the time of enrollmentsubjects are excluded from the study if any of the following&#xD;
        criteria apply:&#xD;
&#xD;
          1. Premature infants (corrected age &lt;37 weeks gestational age)&#xD;
&#xD;
          2. Subjects undergoing Extracorporeal Membrane Oxygenation (ECMO) treatment&#xD;
&#xD;
          3. Fibrinolytic therapy &lt;24 hours before enrollment&#xD;
&#xD;
          4. Lumbar puncture or spinal/epidural catheter placement within the past 48 hours&#xD;
&#xD;
          5. Severe hepatic impairment (Child-Pugh Class C) Note: in patients with&#xD;
             suspected/confirmed severe liver disease, Child-Pugh C stage of liver disease must be&#xD;
             excluded before start of treatment. For calculating Child-Pugh score, laboratory&#xD;
             parameters in the patient file on INR, prothrombin time, serum albumin and total&#xD;
             bilirubin taken can be taken, if they have been obtained within the last 48 hours&#xD;
             before randomization. In all other patients these parameters have to be measured&#xD;
             before start of treatment to identify potential exclusion criteria.&#xD;
&#xD;
          6. Active bleeding&#xD;
&#xD;
          7. Subjects with the following conditions to be excluded if alternative antithrombotic&#xD;
             treatments are available:&#xD;
&#xD;
             (i) Severe hemorrhagic diathesis, (ii) Traumatic damage to the central nervous system&#xD;
             (iii) Brain, spinal or ophthalmologic surgery (iv) Active stomach/duodenal ulcers or&#xD;
             active peptic ulcer unless this ulcer is the cause of the surgical procedure&#xD;
&#xD;
          8. An unexplained activated partial thromboplastin time (aPTT) &gt; 2 x the normal range&#xD;
&#xD;
          9. A hemorrhagic cerebrovascular accident within the previous 3 months&#xD;
&#xD;
         10. Severe, uncontrolled hypertension defined as blood pressure &gt;180/110 mmHg&#xD;
&#xD;
         11. Diabetic retinopathy&#xD;
&#xD;
         12. Acute bacterial endocarditis&#xD;
&#xD;
         13. Expectation of a long-term (&gt; 3 weeks) hemodialysis requirement before the end of the&#xD;
             acute treatment&#xD;
&#xD;
         14. Hypersensitivity to the active substances or to any of the excipients&#xD;
&#xD;
         15. Hypersensitivity to sulphite&#xD;
&#xD;
         16. Any investigational drug(s) use within 4 weeks preceding screening or anticipated use&#xD;
             during the course of the study&#xD;
&#xD;
         17. Pregnant or breastfeeding woman&#xD;
&#xD;
         18. Use of intra-aortic balloon pump, or ventricular assist device&#xD;
&#xD;
         19. Use of any non-heparin anticoagulant treatment for suspected HIT for more than 48&#xD;
             hours before enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shands University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of the Republic of Srpska, Medical Intesnive Care Unit</name>
      <address>
        <city>Banja Luka</city>
        <state>Republika Srpska</state>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre of the Republic of Srpska, Clinic for cardiology</name>
      <address>
        <city>Banja Luka</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre of the Republic of Srpska, Lung Clinic</name>
      <address>
        <city>Banja Luka</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center University of Sarajevo, Clinic for Heart, Blood Vessels and Rheumatic Diseases</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center University of Sarajevo, Clinic for Lung Diseases</name>
      <address>
        <city>Sarajevo</city>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital; 501 Smyth Road</name>
      <address>
        <city>Ottawa</city>
        <state>Ottowa</state>
        <zip>K1H 8l6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIJON University Hospital</name>
      <address>
        <city>Dijon</city>
        <state>Burgundy</state>
        <zip>2100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU St Etienne; Avenue Albert Raimond</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <state>Rhone- Alpes</state>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <state>Somme</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum im Friedrichhain Hämophiliezentrum, Gerinnungssprechstunde Landsberger Allee 49</name>
      <address>
        <city>Berlin</city>
        <state>Berlin-Brandenburg</state>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum im Friedrichhain Hämophiliezentrum</name>
      <address>
        <city>Berlin</city>
        <state>Brandenburg</state>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH, Klinik für Herz-, Kinderherz- und Gefäßchirurgie Standort Gießen</name>
      <address>
        <city>Gießen</city>
        <state>Hesse</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH, Klinik für Herz-, Kinderherz- und Gefäßchirurgie Standort Gießen</name>
      <address>
        <city>Giesen</city>
        <state>Lower Saxony</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatstklinikum Halle (Saale), Medizinische Klinik III</name>
      <address>
        <city>Halle (Saale)</city>
        <state>Saxony-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinkum Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>1067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Greifswald Dpt. of Hematology</name>
      <address>
        <city>Greifswald</city>
        <zip>17489</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Klinische Transfusionsmedizin</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria S.Orsola-Malpighi - UO Angiologia e Malattie della Coagulazione</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Careggi, SOD Malattie Aterotrombotiche</name>
      <address>
        <city>Firenze</city>
        <state>Florence</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XIII, Servizio di Immunoematologia e Medicina Trasfusionale</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardy</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humanitas Research Hospital- Thrombosis Center</name>
      <address>
        <city>Milano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Scientifico San Raffaele- Servizio Coagulazione e Centro Trombosi</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne HCP Sp. z o.o. Szpital im. Św. Jana Pawła II</name>
      <address>
        <city>Poznań</city>
        <zip>61485</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Zespolony im. L. Rydygiera</name>
      <address>
        <city>Toruń</city>
        <zip>87100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First City Hospital N.A. E.E. Volosevich</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Hospital 67</name>
      <address>
        <city>Moscow</city>
        <zip>123423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Center</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Hospital after N.N Burdenko</name>
      <address>
        <city>Penza</city>
        <zip>440026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital № 122 N. A. L.G. Sokolov</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiovasklar Diseases of Vojvodina, Cardiac Surgery ICU</name>
      <address>
        <city>Sremska Kamenica</city>
        <state>Novi Sad</state>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Institute for Pulmonary Disease of Vojvodina, Pulmonary thromboembolism department</name>
      <address>
        <city>Novi Sad</city>
        <state>Sremska Kamenica</state>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Serbia, Clinic for Emergency Internal Medicine</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical centre of Serbia, Clinic for Pulmonology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instiute of Cardiovascular Diseases &quot;Dedinje&quot;</name>
      <address>
        <city>Belgrade</city>
        <zip>11040</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Hungary</country>
  </removed_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 17, 2019</study_first_submitted>
  <study_first_submitted_qc>January 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Danaparoid</mesh_term>
    <mesh_term>Argatroban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

